v3.26.1
Schedule of Earnings Per Share Basic and Diluted (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Net loss attributable to Invo Bioscience, Inc $ 888,740 $ (5,539,351) $ (3,618,969) $ (17,403,586) $ (4,650,611) $ (21,022,555)
Weighted average shares 2,105,595   9,936   1,873,019 7,478
Basic earnings (loss) per common share $ 0.42   $ (364.23)   $ (2.48) $ (2,811.31)
Add interest expense on convertible notes, net of tax zero $ 16,683    
Net income (loss) attributable to INVO for diluted earnings per share $ 905,423   $ (3,618,969)   $ (4,650,611) $ (21,022,555)
Warrants 153,750    
Convertible debt and accrued interest 266,013    
Convertible preferred 66,667    
Diluted weighted-average number of common shares outstanding 2,592,025   9,936   1,873,019 7,478
Diluted net income (loss) per common share $ 0.35   $ (364.23)   $ (2.48) $ (2,811.31)
Share-Based Payment Arrangement, Option [Member]            
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Convertible preferred stock 9,123   9,123   2,072 2,072
Warrant [Member]            
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Convertible preferred stock 1,898,020   2,051,770   528,334 528,334
Convertible Notes and Interest [Member]            
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Convertible preferred stock   266,013   1,007,753 1,007,753
Convertible Preferred Stock [Member]            
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Convertible preferred stock   66,667   10,719 10,719